Liquidia：YUTREPIA（曲前列尼尔）获FDA全面批准推动Q3盈利

文件确认YUTREPIA于2025年5月23日获得FDA全面批准，并于2025年6月在美国正式上市。这是该产品首个完整季度的销售，净收入达5170万美元，实现经营盈利。该批准涵盖PAH和PH-ILD适应症，以改善运动能力。

关键事实

申报时间: 2025年11月3日 11:46
事件: FDA 批准
方向: 积极
公司: LQDALiquidia
资产: treprostinil
来源: SEC 8-K
可信度: 有来源
处方医生: 超过600名
患者启动: 1500例
净产品销售额: 5170万美元
独特处方: 超过2000张

来源摘录

EX-99.1 2 tm2530004d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update · Recorded $51.7 million in net product sales of YUTREPIA™ as launch momentum continues · Achieved profitability in the first full quarter of YUTREPIA sales · More than 2,000 unique patient prescriptions and 1,500 patient starts to date · Company to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., November 3, 2025 – Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced its financial results for the third quarter ended September 30, 2025. The company will also host a webcast at 8:30

SEC 8-K